Gestational diabetes mellitus in relation to serum per- and polyfluoroalkyl substances: A scoping review to evaluate the need for a new systematic review.

Q2 Pharmacology, Toxicology and Pharmaceutics

F1000Research Pub Date : 2024-10-09 eCollection Date: 2023-01-01 DOI:10.12688/f1000research.144376.2

Ghazaleh Aali, Anna K Porter, Sebastian Hoffmann, Matthew P Longnecker, Farhad Shokraneh

{"title":"Gestational diabetes mellitus in relation to serum per- and polyfluoroalkyl substances: A scoping review to evaluate the need for a new systematic review.","authors":"Ghazaleh Aali, Anna K Porter, Sebastian Hoffmann, Matthew P Longnecker, Farhad Shokraneh","doi":"10.12688/f1000research.144376.2","DOIUrl":null,"url":null,"abstract":"Background: Per- and polyfluoroalkyl substances (PFAS) were used or are being used in the manufacturing of products, including consumer-use products. The resulting environmental contamination has led to widespread human exposure. This review aimed to scope the characteristics of evidence covered and applied methodology of evidence to understand -- regardless of any results on the association of gestational diabetes mellitus (GDM) and PFAS -- if a new systematic review would be justified.Methods: We systematically identified reports investigating associations of PFAS with GDM following a pre-specified and pre-registered PECO framework and protocol.Results: The previous systematic reviews included 8-11 reports and either conducted meta-analyses stratified by comparator, analyzed results based on only high and low exposure categories, or pooled results across comparators. Included 20 reports presented data on 24 PFAS with PFOA, PFOS, PFHxS, PFNA, and PFDA being examined in almost all. The comparators employed were heterogeneous across the reports.Conclusions: Because data from at least one new report on GDM is available since the previous systematic reviews and heterogeneous comparators, an updated systematic review using SWiM could add value to the literature.","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"12 ","pages":"1595"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474155/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.144376.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Per- and polyfluoroalkyl substances (PFAS) were used or are being used in the manufacturing of products, including consumer-use products. The resulting environmental contamination has led to widespread human exposure. This review aimed to scope the characteristics of evidence covered and applied methodology of evidence to understand -- regardless of any results on the association of gestational diabetes mellitus (GDM) and PFAS -- if a new systematic review would be justified.

Methods: We systematically identified reports investigating associations of PFAS with GDM following a pre-specified and pre-registered PECO framework and protocol.

Results: The previous systematic reviews included 8-11 reports and either conducted meta-analyses stratified by comparator, analyzed results based on only high and low exposure categories, or pooled results across comparators. Included 20 reports presented data on 24 PFAS with PFOA, PFOS, PFHxS, PFNA, and PFDA being examined in almost all. The comparators employed were heterogeneous across the reports.

Conclusions: Because data from at least one new report on GDM is available since the previous systematic reviews and heterogeneous comparators, an updated systematic review using SWiM could add value to the literature.

查看原文本刊更多论文

妊娠糖尿病与血清全氟和多氟烷基物质的关系：为评估是否需要开展新的系统性研究而进行的范围界定研究。

背景：全氟和多氟烷基物质 (PFAS) 曾经或正在被用于制造产品，包括消费品。由此造成的环境污染已导致人类广泛接触。本综述旨在对所涵盖的证据特点和应用的证据方法进行归纳，以了解--无论妊娠糖尿病（GDM）与 PFAS 的关联性是否有任何结果--是否有理由进行新的系统性综述：方法：我们按照预先指定和注册的 PECO 框架和协议，系统地确定了调查 PFAS 与 GDM 关联性的报告：之前的系统性综述包括 8-11 篇报告，这些报告或按参照物进行分层荟萃分析，或仅根据高、低暴露量类别分析结果，或汇总不同参照物的结果。所纳入的 20 份报告提供了 24 种 PFAS 的数据，几乎所有报告都对 PFOA、PFOS、PFHxS、PFNA 和 PFDA 进行了研究。各报告采用的参照物不尽相同：由于自之前的系统综述以来，至少有一份关于 GDM 的新报告提供了数据，而且采用的参照物也不尽相同，因此使用 SWiM 进行最新的系统综述可为文献增添价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.00

自引率

0.00%

发文量

1646

审稿时长

1 weeks

期刊介绍： F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.